Twist Bioscience Corporation
A maker of synthetic DNA, Twist Bioscience writes custom genes and gene fragments on tiny silicon chips, shrinking the synthesis process dramatically. Its tools help researchers and drug developers discover and optimize antibodies, while its NGS products—target enrichment probes, library prep kits, and synthetic controls—are used in diagnostic tests for cancer, rare disease, and infectious disease. The company serves over 3,800 customers worldwide.
Granted 75.4K · Sold 162.7K
Granted 23.4K · Sold 91.7K
Granted 26.1K · Sold 32.4K
Sold 17.6K
Sold 49.3K
Granted 10.0K · Sold 10.0K
Sold 9.7K
Granted 12.0K · Sold 12.0K
Sold 4.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leproust Emily M.Chief Executive Officer, Director · 28 transactions | -10.7% | 770.7K | 75.4K | — | 162.7K |
| Finn Patrick JohnPresident and COO · 12 transactions | -25.8% | 210.8K | 23.4K | — | 91.7K |
| Green PaulaSVP of Human Resources · 10 transactions | -5.9% | 117.9K | 26.1K | — | 32.4K |
| Laponis AdamChief Financial Officer · 6 transactions | -15.3% | 108.6K | — | — | 17.6K |
| Cho DennisSee Remarks · 10 transactions | -46.6% | 74.1K | — | — | 49.3K |
| Chess RobertDirector · 2 transactions | 0% | 63.6K | 10.0K | — | 10.0K |
| Werner Robert F.Chief Accounting Officer · 10 transactions | -18.9% | 44.6K | — | — | 9.7K |
| Johannessen JanDirector · 2 transactions | +67.6% | 29.8K | 12.0K | — | 12.0K |
| Starovasnik Melissa A.Director · 4 transactions | -16.8% | 22.2K | — | — | 4.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -390.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.